Gemtuzumab

In the US, Gemtuzumab (gemtuzumab systemic) is a member of the drug class CD33 monoclonal antibodies and is used to treat Acute Myeloid Leukemia.

US matches:

• Gemtuzumab Ozogamicin


• Gemtuzumab


• Gemtuzumab Intravenous


• Gemtuzumab ozogamicin Intravenous

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XC05

CAS registry number (Chemical Abstracts Service)

0220578-59-6

Therapeutic Categories

Antineoplastic agent

Immunomodulator

Chemical Name

Immunoglobulin G4 (human-mouse monoclonal hP67.6 gamma 4-chain anti-human antigen CD 33), disulfide with human-mouse monoclonal hP67.6 gamma-chain, dimer (WHO)

Foreign Names

• Gemtuzumabum (Latin)
• Gemtuzumab (German)
• Gemtuzumab (French)
• Gemtuzumab (Spanish)

Generic Names

• Gemtuzumab Ozogamicin (OS: USAN)
• CDP 771 (IS: WyethAyerst)
• CMA 676 (IS: WyethAyerst)
• Gemtuzumab zogamicin (IS)
• hP67.6-calicheamicin (IS)
• WAY-CMA 676 (IS: WyethAyerst)

Brand Names

• Mylotarg
  Pfizer, Switzerland; Wyeth, Argentina; Wyeth, Colombia; Wyeth, United States; Wyeth, Venezuela; Wyeth KK, Japan

International Drug Name Search

Glossary

IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.